HUNTERSVILLE, N.C., Sept. 18, 2026 /PRNewswire/ -- BioCytics, Inc., has engaged Eremid® Genomic Services to help sequence an autologous immune cell fraction that is the leading candidate of BioCytics' immune-based cancer cell therapy efforts. Eremid will perform single cell transcriptomic (scRNA-Seq) and TCR sequencing analysis of immune cells provided by BioCytics.
BioCytics is focused on developing an autologous adaptive immune cell therapy that provides a personalized treatment for solid tumors, using the patients' own immune cells that have been activated against their own cancer. Briefly, patient's rare immune precursor cells are isolated from leukapheresis products and are massively expanded and re-invigorated in culture to ensure there are sufficient biologically fit cells to be reinfused into the patient to fight the tumor. BioCytics needs to further characterize both the precursors and expanded cells prior to clinical use. Using data from an scRNA-Seq analysis will confirm the readiness of the immune cells for cancer-killing capability and provide comprehensive view of mode of actions.
Dr. Renaud Warin, BioCytics CSO, says "Transcriptomics studies are central to the unders...